Jogender Tushir-Singh

Relationship source ↗ (external link)

Affiliations reported with papers

• Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA; UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California, USA.2026 publication record
• Laboratory of Novel Biologics, University of California Davis, Davis, CA, USA. jtsingh@ucdavis.edu.2025 publication record
• Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA. jtsingh@ucdavis.edu.2025 publication record
• Department of Obstetrics and Gynecology, UC Davis School of Medicine, University of California Davis, Davis, CA, USA. jtsingh@ucdavis.edu.2025 publication record
• UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, University of California Davis, Davis, CA, USA. jtsingh@ucdavis.edu.2025 publication record

Linked publications

An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities 2026

The functional crosstalk between tissue transglutaminase (TG2) and CD24 enhances cancer stem cell traits and therapy resistance in high grade serous ovarian cancer 2026

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy 2025

Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype 2025

The TRIM37 variant rs57141087 contributes to triple-negative breast cancer outcomes in Black women 2025

Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer 2023

A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle 2022

Bispecific antibodies for the treatment of breast cancer 2022

A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors 2021

Arming "old guards" with "new dual-targeting weapons" 2021

Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies 2021

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody 2020

Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer 2020

Targeting HER2 beyond breast cancer 2019

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer 2018

Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice 2018

Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy 2017

In Vitro Assay to Study Histone Ubiquitination During Transcriptional Regulation 2017

Human-specific histone methylation signatures at transcription start sites in prefrontal neurons 2012

Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts morphogenesis 2010

SnapShot: Fly piRNAs, PIWI proteins, and the ping-pong cycle 2009

SnapShot: mouse piRNAs, PIWI proteins, and the ping-pong cycle 2009

ARF6-dependent activation of ERK and Rac1 modulates epithelial tubule development 2007

Related research

Human FasL, evolution and plasmin cleavage

A macaque TIGIT shedding difference

The regulatory Fas epitope

FOLR1-anchored DR5 bispecific antibody

DR5 agonism and PD-L1 immune evasion

Surface charge and DR5 antibody response

TRIM37 in breast-cancer outcomes

X-chromosome reactivation in Rett research

Furin disruption in SARS-CoV-2 models